We are live on ! Find out more
PDLI

PDL BioPharma, Inc.
PDLI

Delisted

PDLI was delisted on the 30th of December, 2020.

Back to rankings

11 hedge funds and large institutions have $36.7M invested in PDL BioPharma, Inc. in 2021 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

65% less capital invested

Capital invested by funds: $104M → $36.7M (-$67.2M)

67% less funds holding

Funds holding: 33 → 11 (-22)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 21

Holders
11
Holders Change
-22
Holders Change %
-66.67%
% of All Funds
0.19%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
1
Reduced
–
Closed
21
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PPA
Parametric Portfolio Associates
Washington
+$2.07K

Top Sellers

Rank Fund Capital Flow
1
SPC
Silver Point Capital
Connecticut
-$58.7M
2
GCIA
Gabelli & Co Investment Advisers
New York
-$1.56M
3
JC
JBF Capital
Colorado
-$1.34M
4
GF
Gabelli Funds
New York
-$1.27M
5
CCM
Context Capital Management
California
-$1.15M

PDLI Hedge Fund Activity: Q1 2021 in Review

11 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in PDL BioPharma, Inc. (PDLI) for Q1 2021, worth a combined $36.7M — down 65% from $104M a quarter earlier.

Sellers outnumbered buyers: 21 funds closed out of PDLI and 0 opened new positions — a net loss of 21 holders — while 0 trimmed existing stakes and 1 added.

The largest buyer was Parametric Portfolio Associates, adding an estimated $2.07K. The largest seller was Silver Point Capital, exiting entirely with an estimated $58.7M sold.

  • 11 institutional investors held PDL BioPharma, Inc. (PDLI) as of Q1 2021, down from 33 in Q4 2020.
  • Funds reported $36.7M of PDL BioPharma, Inc. stock for Q1 2021, down 65% quarter-over-quarter.
  • 0 funds opened new PDL BioPharma, Inc. positions in Q1 2021 and 21 closed out, a net change of -21 holders.
  • The largest PDL BioPharma, Inc. buyer in Q1 2021 was Parametric Portfolio Associates, an estimated $2.07K added.
  • The largest PDL BioPharma, Inc. seller in Q1 2021 was Silver Point Capital, an estimated $58.7M sold.

Based on aggregated 13F filings for Q1 2021.